Senesco Technologies, Inc. (OTCMKTS:SNTI) Takes a Breather as Promotion Goes Silent

Despite the constant new studies, and a bright outlook, Senesco Technologies, Inc. (OTCMKTS:SNTI) could not manage a third wild day in a row, and retreated slightly on lower volumes. SNTI is at 5 cents after losing 7% as stocks worth more than $463,000 were sold off. At 2 cents, the company was deemed wildly underpriced, but at 5 cents, the price does not seem so enticing.

The company has no new press releases, and still no promotional email, so it’s a wait-and-see situation. Fundamentally, SNTI is an active pharmaceutical developer, although still without large marketing success:

• $1.5 million cash

• $6.8 million total assets

• $3.5 million total liabilities

• Still zero revenues

• $61 million net loss since inception

• $986,719 quarterly loss

The next few days will show if SNTI manages to go upward again, especially if it underlines new trials or new phases for its proposed treatments. It is unclear if the newest research with a cohort of patients would be done by August, as the company suggested, or by October, as other sources mention. In any case, the interest should be somewhat stoked by the expected results.

Biopharmaceutical companies usually move as a group amid penny stocks, and SNTI is a newcomer. Other names have almost become fixtures, such as AP Pharma, Inc. (OTCBB:APPA), which is enjoying medium-range, yet predictable interest. APPA moves mostly sideways, with a trend in the months-long term. The ticker is now at 43 cents, after losing around 6% on Thursday.

Another contender is currently in a peak of optimism. Anavex Life Sciences, Corp. (OTCMKTS:AVXL) is peaking at 74 cents on a fourth day of consecutive buying. The company was boosted by a series of paid emails in August, and this shows the difference between a promoted pharmaceutical stock and one that moves on the company’s natural influence over investors.

When you choose a ticker from the sector, it is best to do your own due diligence, and discern the causes of upward trends. Pharmaceutical companies rely heavily on future expectations, and often bad news will cause a correction that is much higher than for other tickers, up to 75% off the stock’s value, in some cases. While SNTI may offer a run in the near future, the new higher price is unknown territory, so it is best to avoid investing unless you can also afford a correction.